Three Motley Fool contributors think they've identified dirt-cheap healthcare stocks to buy right now. Here's why they picked CRISPR Therapeutics (NASDAQ: CRSP), Gilead Sciences (NASDAQ: GILD), and ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Vertex Pharmaceuticals Inc. closed $45.72 below its 52-week high ($510.64), which the company achieved on August 1st.

Robert W. Baird has recently initiated Vertex Inc (VERX) stock to Outperform rating, as announced on July 23, 2024, according to Finviz. Earlier, on March 1, 2024, BofA Securities had raised the stock ...

Shares of Vertex Pharmaceuticals Inc. VRTX inched 0.79% higher to $477.90 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 ...

Industry insiders hope the Fed’s decision to cut rates for the first time in years will boost biotech investment. But the long-awaited move won’t cure all that ails the sector, others cautioned.

It’s been almost a year since the Food and Drug Administration approved the first genetic treatments for sickle cell disease.

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” second ...

Haystack, a leading modern intranet provider, today announced its collaboration with Google Cloud to integrate Google Cloud’s ...

(NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, today announced the launch of Vertex for Salesforce Revenue Cloud. This integration brings together Vertex’s ...

Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, has been announced at Oracle CloudWorld the winner in the 2024 Oracle Partner Awards – Best in ...